EPHAR 2024 Abstract Submission Guidelines
A. General Information
a) Please submit your Abstracts online, by using the online abstract submission form. Abstracts sent by email cannot be accepted.
b) Following successful online submission, you will receive by e-mail an “Abstract Submission Confirmation”, indicating that your abstract was received in good order. This confirmation message contains a number which must be referred to in all correspondence related to the submitted abstract. Please save this message on your computer, as it will serve as confirmation of successful abstract submission.
c) If you do not receive this Abstract Submission Confirmation message within a few minutes from your submission, then your abstract was not submitted successfully (i.e, was not registered in the database). In this case, you are kindly requested to repeat the procedure, or to contact the Professional Congress Organizer for further information and assistance.
d) Submission of an abstract constitutes a commitment by the author(s) to present it at the Meeting, if it is accepted. At least one author of each accepted abstract must register for the Meeting before March 15th , 2024. Accepted abstracts of which no author registers for the meeting by this date will be excluded from the Scientific Program. Each registration can correspond to a maximum of (3) three abstract presentations.
e) Abstract submission deadline: December 17th, 2023, at midnight Eastern European Time. Notification to authors will be sent via email by February 15th, 2024.
B. Technical requirements
a) Language: All abstracts should be submitted and presented in English, which is the official language of the Congress, using accurate grammar and spelling suitable for publication. Abstracts will be reproduced exactly as submitted. No proofreading will be done.
b) Corresponding Author: The abstract submission form should be completed by the Corresponding Author, who will be responsible for all future communications regarding the submitted abstract.
c) Each submitter (Corresponding Author) is required to create a user account indicating an account email address and a password. The email and password indicated will be used for all online forms of the Meeting (namely, the Registration Form).
d) Abstract Withdrawal: If, at any time, you wish to withdraw an abstract successfully submitted, please notify us as quickly as possible, stating the title and number of the abstract to be withdrawn. Please note that withdrawal will still be possible after the submission deadline but no later than February 1st, 2024.
B. Format & Online submission requirements and instructions
For the purposes of this meeting, clinical studies are those involving patients or human
volunteers, NOT those using human tissues/cells.
When submitting your abstract, the corresponding author must confirm that the work
meets the required ethical standards for experimentation as follows:
– For research using animals/animal tissues, all procedures meet the following
requirements of the EU Directive 2010/EU/63, or for work carried out elsewhere, all procedures meet with current equivalent national legislation/guidelines.
– For medical research involving human subjects, including research on identifiable
human material and data, the World Medical Association (WMA) Declaration of
Helsinki as a statement of ethical principles has been adhered to, and procedures
concur with equivalent standards set by the relevant national or institutional body.
The organizing committee reserves the right to reject work that does not appear to comply with the directives above.
Maximum 35 words, typed in Sentence-case, except for abbreviations and study names.
You can select your preference between Oral or Poster Presentation, or state that you have no preference. Please note that the Scientific Committee will make final decisions regarding acceptance to oral or poster presentation, considering scientific value, author’s preferences and scientific program limitations. If your abstract is accepted for an oral presentation, you will be asked to present it in-person during the Congress. Oral presenters will have 15 minutes, including questions, so we recommend presenting for a maximum of 12 minutes.
You will be asked to select the topic to which your abstract corresponds the most.
Names of authors should be written in upper/lower cases in the following way:
1. Full name with first letter in upper case (e.g. John)
2. Surname (Family Name) with first letter in upper case (e.g. Smith)
Affiliation details (affiliation name, city, state -if applicable- and country) should be stated in the form.
Instructions on how to structure your abstract
There is a 400- word limit for the text body of the abstract (excluding title, authors, and affiliations, but including references). Nonstandard abbreviations should be defined. New drugs should include their full chemical name. Nomenclature used in your article must follow that of the IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/
Introduction The Introduction should outline the research question and must include a clearly defined purpose or hypothesis for investigation.
Methods In general Methods should contain enough detail to allow others to repeat the study. Core methodological papers may be cited. Species and strain (or human population characteristics) and group sizes must be indicated. Use of drugs (including anaesthetics) requires: solvent, dose and route of administration, or concentration. Investigations of natural product extracts should contain information on chemical/biochemical characterisation. (Please refer to the BJP guidelines on natural products.)
Results The Results section must contain numerical data (including n values) and where appropriate statistical analysis. Use of figures and tables is not allowed.
Conclusions Conclusions should be comprehensible and logical, and not contain unjustified speculation.
References References should be cited using the AMA (American Medical Association) style. All references should be numbered consecutively in order of appearance and should be as complete as possible. In-text citations should be numbers in square brackets e.g. , , etc. Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE, Index Medicus, or CalTech Library. References should be limited to 3.
D. Abstract evaluation & Authors’ notification
All successfully submitted abstracts will be evaluated by the Scientific Committee, which will also determine whether each accepted abstract will be presented orally or as poster, as well as the day and time of presentation. A decision email message will be sent to the Corresponding Author (abstract submitter). EPHAR2024 will only have one round of review for submitted abstracts. To be eligible for a prize, authors must attend the congress in person for onsite review.
Statements of Originality and Copyright Transfer
By submitting an abstract to this Scientific Meeting, the submitting-corresponding author provides, on behalf of all co-authors, their consent to have names, affiliations and biographical material being used in connection with the publication of your work.
Furthermore, the author(s) attest and warrant that they are sole authors of the work, that all co-authors have participated in and agree with the content and conclusions of the work, and that the work is original (except for extracts from copyrighted works fully authorized by the copyright holders) and does not infringe upon any copyright, proprietary, or personal right of any third party, and that all statements declared as facts are based on thorough examination and investigation for accurateness.
The corresponding author signs for all co-authors, and accepts responsibility for adhering to the present rules for submission and presentation on behalf of all co-authors.
The content of each submitted abstract is the property of the author(s). However, if the abstract is accepted, the submitter agrees, on behalf of all co-authors, to transfer and assign to the organizers the rights to publish, reproduce, distribute copies and prepare derivative works such as press releases. This includes use in indexes or search databases in print, electronic, or other media.
The author(s) retain the right, after presentation at the Meeting, to subsequently include the work in articles, books, or derivative works provided said use does not imply the endorsement of the organizers.
By certifying that you have read these Submission rules, you also confirm having received the prior approval from the co-authors to provide their data to the organizers. The information you supply on this application is required to process it and it will be held in the organizers’ customer data files. It may be used for marketing and communication purposes by the organizers and its contractors only. You have the absolute right to access, amend and oppose any use of this personal data by writing to the organizers.